MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer.

摘要: Prostate cancer is the most prevalent nonskin and a major cause of cancer-related deaths worldwide. Prostate-specific antigen (PSA) testing routinely used for screening early detection prostate cancer; however, it does not reduce death from cancer. Moreover, PSA specific results in high false-positive rates, poorly correlated with stage. Therefore, need another diagnostic prognostic factor apparent. MicroRNAs (miRNAs) are small, single-stranded, noncoding RNAs which involved modulation gene expression posttranscriptionally. Multiple lines evidence indicate that miRNAs play key roles various physiological events. Deregulation related to initiation development diseases such as It has been shown (miR-34, miR-21, miR-155, miR-221, miR-222, let-7) exert their effects by targeting variety cellular molecular pathways (c-Myc, EZH2, c-RSC, BCL2L2, E2F6, ZEB, HMGA251, CCND2) pathogenesis. Hence, seems miRNA profiles can be seen potential candidates prognosis, diagnosis, treatment Here, we summarize prognostic, diagnostic, therapeutic biomarkers therapy.